Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Survival Analysis MeSH
- Angiopoietin-2 blood genetics metabolism MeSH
- ADP-ribosyl Cyclase 1 blood metabolism MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell blood metabolism physiopathology MeSH
- Adult MeSH
- Gene Expression * MeSH
- Genes, Immunoglobulin Heavy Chain MeSH
- Cohort Studies MeSH
- Leukocytes, Mononuclear metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Membrane Glycoproteins blood metabolism MeSH
- RNA, Messenger metabolism MeSH
- Biomarkers, Tumor blood genetics metabolism MeSH
- Polymerase Chain Reaction MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Aged MeSH
- Immunoglobulin Variable Region genetics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Angiopoietin-2 MeSH
- ADP-ribosyl Cyclase 1 MeSH
- CD38 protein, human MeSH Browser
- Membrane Glycoproteins MeSH
- RNA, Messenger MeSH
- Biomarkers, Tumor MeSH
- Immunoglobulin Variable Region MeSH
Several studies have demonstrated the potential prognostic importance of angiogenesis in chronic lymphocytic leukemia (CLL). Elevated expression of angiopoietin-2 (Ang-2), an angiogenic cytokine, was recently reported in CLL. However, data regarding prognostic significance of Ang-2 in CLL are limited. Therefore, we quantitated Ang-2 mRNA in purified mononuclear cells of 33 untreated CLL patients and compared the transcript levels to traditional as well as modern prognostic factors in patients with CLL (clinical stage, disease course, IgVH mutation status, CD38, and ZAP-70 expression). Elevated Ang-2 mRNA concentrations were detected in 12 cases; 21 patients had very low or undetectable levels of Ang-2 transcript. There was significant association between high Ang-2 mRNA levels and unmutated IgVH genes (n=27, P=0.010) and with CD38 expression (n=32, P=0.011), but not with ZAP-70 expression (n=32, P=0.784), Rai stage (n=33, P=0.305) or stable versus progressive clinical course (n=33, P=0.443). There was a trend towards shorter progression-free survival in patients with high Ang-2 expression; however, it did not reach statistical significance (P=0.090). Our pilot data show that Ang-2 mRNA is differentially expressed in patients with CLL and its increased expression appears to be associated with poor prognostic features. Further studies are needed to confirm the results in a larger patient cohort.
References provided by Crossref.org